Bal Pharma share news, announcements and annual reports
NSE: BALPHARMABSE: 524824Pharmaceuticals & BiotechnologySmall Cap
Bal Pharma Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, May 2006 on NSE
Last close ₹84.61down ₹1.56 (1.81%)BSE ₹84.35
Share price at the NSE close on 29 Oct 2026. Previous close ₹86.17.
29 Oct: open ₹86.50, high ₹86.89, low ₹84.12
52-week range of traded prices to 29 Oct 2026
₹60.00Low, 30 Mar 2026₹124.60High, 10 Sep 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹135 Cr2,779th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 18.69
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.64
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.42%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.94
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2,181
Bal Pharma board and management
31 filed, newest first.
Sep 2026
25 Sep · Management
May 2026
12 May · Management
Sep 2025
30 Sep · Management
May 2025
5 May · Management
Jun 2024
28 Jun · Management
Aug 2023
Jul 2023
May 2023
Nov 2022
Dec 2020
Feb 2020
Sep 2019
Jun 2019
29 Jun · Management
Mar 2019
Dec 2018
Oct 2017
Aug 2016
Dec 2015
Jul 2015
Mar 2015
Jun 2014
Jan 2014
Jul 2012
26 Jul · Management
Vide letter dated July 26, 2012 that Mr.Venkatesan Murali is appointed as General Manager Finance and Company Secretary of the Company. Mr. Venkatesan Murali is also designated as the Compliance officer of the Company.
Aug 2011
12 Aug · Management
Mr. D. Muarali has been appointed as the Company Secretary & Compliance Officer, in place of Mr. S. Ramji who has resigned from the Company on personal grounds. Mr.D. Muarali, will be the Chief Financial Officer of the Company.
May 2011
13 May · Management
Mr. Ajit Kumar has been appointed as the new Nominee Director of the Export Import Bank of India on the Board in place of Mr. David Rasquinha who has been resigned from the Directorship as part of the rotation policy of the Export Import Bank of India.
Jul 2007
5 Jul · Management
Mr.S.Ramji, has been appointed as Company Secretary & Compliance Officer of Bal Pharma Limited, w.e.f. 18.06.2007 in place of Mr.K.Mahadevan, Company Secretary & Compliance Officer.
Jun 2007
11 Jun · Management
Mr. N.D Prabhu, (Independent Director) & Mr. A. R Hegde, (Additional Director), has resigned from the Directorship of Bal Pharma Limited due to personal reasons, w-e-f 01.04.2007 & 30.05.2007. The Meeting of the Board of Directors of the Company held on 31.05.2007-accepted resignations of Mr.N.D Prabhu & Mr. A.R. Hegde
Mar 2007
21 Mar · Management
Exim Bank of India has appointed Mr. David Rasquinha, General Manager, Exim Bank of India as their Nominee Director on the Board of the company in terms of their Term Loan covenant and he shall hold office at the pleasure of the Exim Bank. His appointment is not taken into account for the number of Directors who retire by rotation